Deficiency in the LIM-only protein Fhl2 impairs skin wound healing

Viktor Wixler,1 Stephanie Hirner,3 Judith M. Müller,4 Lucia Gullotti,3 Carola Will,1 Jutta Kirfel,3 Thomas Günther,4 Holm Schneider,2 Anja Bosserhoff,4 Hubert Schorle,2 Jung Park,7 Roland Schüle,4 and Reinhard Buettner3

1Institute of Molecular Virology, Münster University Hospital Medical School, D-48149 Münster, Germany
2Department of Developmental Pathology, 3Institute of Pathology, University Hospital Medical School, D-53127 Bonn, Germany
4Center for Clinical Research, University of Freiburg, D-79106 Freiburg, Germany
5Experimental Neonatology, Department of Pediatrics, Medical University of Innsbruck, Innrain 66, A-6020 Innsbruck, Austria
6Institute of Pathology, University Hospital Regensburg, D-93042 Regensburg, Germany
7Department of Experimental Medicine I, University of Erlangen-Nürnberg, D-91054 Erlangen, Germany

After skin wounding, the repair process is initiated by the release of growth factors, cytokines, and bioactive lipids from injured vessels and coagulated platelets. These signal molecules induce synthesis and deposition of a provisional extracellular matrix, as well as fibroblast invasion into and contraction of the wounded area. We previously showed that sphingosine-1-phosphate (S1P) triggers a signal transduction cascade mediating nuclear translocation of the LIM-only protein Fhl2 in response to activation of the RhoA GTPase (Müller, J.M., U. Isele, E. Metzger, A. Rempel, M. Moser, A. Pscherer, T. Breyer, C. Holubarsch, R. Buettner, and R. Schule. 2000. EMBO J. 19:359–369; Müller, J.M., E. Metzger, H. Greschik, A.K. Bosserhoff, L. Mercep, R. Buettner, and R. Schule. 2002. EMBO J. 21:736–748.). We demonstrate impaired cutaneous wound healing in Fhl2-deficient mice rescued by transgenic expression of Fhl2. Furthermore, collagen contraction and cell migration are severely impaired in Fhl2-deficient cells. Consequently, we show that the expression of α-smooth muscle actin, which is regulated by Fhl2, is reduced and delayed in wounds of Fhl2-deficient mice and that the expression of p130Cas, which is essential for cell migration, is reduced in Fhl2-deficient cells. In summary, our data demonstrate a function of Fhl2 as a lipid-triggered signaling molecule in mesenchymal cells regulating their migration and contraction during cutaneous wound healing.

Introduction

In recent years, considerable progress has been made in understanding the role of growth factors and cytokines in wound healing. These factors are released from injured vessels and coagulated platelets and trigger an inflammatory response that initiates the deposition of a provisional extracellular matrix. In parallel, mesenchymal and endothelial precursor cells invade the wound to form the granulation tissue and to contract the wounded area.

Contraction of the granulation tissue by mesodermal fibroblasts is of high importance for sealing the wound, as it helps to bring the wound margins together. To be able to contract efficiently, mesenchymal cells of the granulation tissue differentiate into myofibroblasts characterized by a well-developed cytoskeleton. Myofibroblasts express α-smooth muscle actin (α-SMA), which is incorporated into actin stress fibers and enables them to develop much higher mechanical forces (Hinz and Gabbiani, 2003). Hence, induction of α-SMA expression in fibroblasts is a critical step in wound healing.

Besides growth factors and cytokines, bioactive lipids have been identified as important signal molecules, modulating inflammatory responses, cell growth, and tissue formation. However, the role of lipid-induced signaling and its contribution to wound healing is still poorly understood. We previously showed that sphingosine-1-phosphate (S1P) triggers a signal transduction cascade mediating nuclear translocation of the LIM-only protein Fhl2 in response to activation of the RhoA GTPase (Muller et al., 2000, 2002). We and others further identified the LIM-only protein Fhl2 as interacting with transcription factors, including androgen receptor (Muller et al., 2002), serum response factor (SRF; Philipp et al., 2004; Purcell et al., 2004), Jun, and Fos (Morlon and Sassone-Corsi, 2003), as well as with integrin receptors (Wixler et al., 2000; Samson et al., 2004).
Bars: (A) 50 μm; (B) 25 μm.

α(SMA) (arrows, red AEC stain) label -SMA– and SM22-positive myofibroblasts. Immunostaining of human wound tissue indicates that Fhl2 immunosignals cells present in dermal granulation tissue 5 d after wounding. (B) Double α reveals strong up-regulation of Fhl2 in -SMA–positive myofibroblast-like cells of the granulation tissue, but not in differentiated fibroblasts from normal skin (Fig. 1 A). The myofibroblasts are characterized by α-SMA and SM22 immunoreactivity and, importantly, double-immunostainings of tissue sections for both Fhl2 (Fig. 1 B, red stain) and α-SMA or SM22 (Fig. 1 B, brown stain) indicated that the most abundant site of Fhl2 expression in the granulation tissue are indeed myofibroblasts. In contrast, keratinocytes did not reveal any Fhl2 immunoreactivity. These results, along with data obtained from human skin biopsies in vivo and from serum stimulation of cell lines, indicated that Fhl2 is up-regulated in myofibroblasts during wound healing and that it shuttles into the nucleus in response to exposure to bioactive lipids present in blood, as previously described (Muller et al., 2002; Morlon and Sassone-Corsi, 2003; Philippar et al., 2004).

We applied punch biopsy wounds to skin and cutaneous muscle of wild-type (Fhl2/+) and Fhl2-deficient (Fhl2−/−) mice and conclusively found significant up-regulation of both Fhl2 mRNA and protein expression in Fhl2−/− mice during skin regeneration, with a maximum at 5 d after wounding (Fig. 2, A and B). In contrast, Fhl2−/− mice lack Fhl2 mRNA and protein expression (Fig. 2, A and B). Intermediate levels of Fhl2 were induced in wounds of mice carrying a SM22 promoter-driven Fhl2 transgene in a Fhl2−/− genetic background (Fhl2−/−tgSM22Fhl2). Interestingly, Fhl2−/− mice revealed severely impaired wound healing because only 10% of skin wounds were closed after 5 d, compared with 40% in Fhl2+/− mice (Fig. 2 C). After 12 d, all wounds of Fhl2+/− mice were closed, whereas only 80% were closed in Fhl2−/− mice. Importantly, the Fhl2−/−tgSM22Fhl2 transgenic mice that express intermediate Fhl2 mRNA and protein levels in a Fhl2−/− genetic background, displayed a nearly wild-type phenotype, with 30 and 90% wound closure at days 5 and 12, respectively, demonstrating rescue of the wound closure phenotype of Fhl2−/− mice. The same SM22Fhl2 transgene expressed in a Fhl2+/− background, however, did not influence wound healing, indicating that the high levels of Fhl2 expression in Fhl2−/− mice are both necessary and sufficient for efficient wound healing. At each time point, 38–42 lesions were evaluated by measuring wound closure macroscopically, as well as by histological and immunohistochemical staining of skin sections. Collectively, our data indicate that the efficiency of wound closure correlates with the amount of Fhl2 mRNA and protein expression in wounds.

Fibroblasts play a key role in the formation of mechanical forces that lead to wound contraction, which is required to bring the wound margins together. Therefore, we were interested in

and signal transducers such as β-catenin (Martin et al., 2002). Fhl2 associates with integrins at focal adhesion sites and is translocated into the nucleus upon stimulation by serum or S1P to modulate transcriptional activity of numerous target genes. Because significant amounts of S1P and lysophosphatidic acid are released from platelets during tissue repair (Yatomi et al., 2000), we investigated the role of Fhl2 signaling in mesenchymal cells during wound healing.

**Results**

Previous studies of Fhl2 in prostate cancer revealed its expression in the prostate cancer cells proper, but also in myofibroblast-like cells within the stroma (Muller et al., 2000, 2002). To confirm expression and regulation of Fhl2 in mesenchymal cells, we isolated primary embryonic mouse fibroblasts and visualized Fhl2 expression and nuclear translocation in response to serum exposure. When fibroblasts were starved in 0.5% FCS, and then exposed to 10% FCS for 24 and 48 h, respectively, we observed both significant up-regulation of Fhl2 mRNA and nuclear translocation of the respective protein (Fig. S1, available at http://www.jcb.org/cgi/content/full/jcb.200606043/DC1), as previously described (Muller et al., 2002). More importantly, we observed strong up-regulation of Fhl2 in α-SMA–positive mesenchymal cells of wounded skin (Fig. 1 A). A series of five different tissue specimens obtained 5–14 d after wounding were analyzed by Fhl2 immunostaining. In all cases, we observed very strong signals present in the cytoplasm and the nucleus of myofibroblast-like cells of the granulation tissue, but not in differentiated fibroblasts from normal skin (Fig. 1 A). The myofibroblasts are characterized by α-SMA and SM22 immunoreactivity and, importantly, double-immunostainings of tissue sections for both Fhl2 (Fig. 1 B, red stain) and α-SMA or SM22 (Fig. 1 B, brown stain) indicated that the most abundant site of Fhl2 expression in the granulation tissue are indeed myofibroblasts. In contrast, keratinocytes did not reveal any Fhl2 immunoreactivity. These results, along with data obtained from human skin biopsies in vivo and from serum stimulation of cell lines, indicated that Fhl2 is up-regulated in myofibroblasts during wound healing and that it shuttles into the nucleus in response to exposure to bioactive lipids present in blood, as previously described (Muller et al., 2002; Morlon and Sassone-Corsi, 2003; Philippar et al., 2004).

We applied punch biopsy wounds to skin and cutaneous muscle of wild-type (Fhl2+/+) and Fhl2-deficient (Fhl2−/−) mice and conclusively found significant up-regulation of both Fhl2 mRNA and protein expression in Fhl2−/− mice during skin regeneration, with a maximum at 5 d after wounding (Fig. 2, A and B). In contrast, Fhl2−/− mice lack Fhl2 mRNA and protein expression (Fig. 2, A and B). Intermediate levels of Fhl2 were induced in wounds of mice carrying a SM22 promoter-driven Fhl2 transgene in a Fhl2−/− genetic background (Fhl2−/−tgSM22Fhl2). Interestingly, Fhl2−/− mice revealed severely impaired wound healing because only 10% of skin wounds were closed after 5 d, compared with 40% in Fhl2+/− mice (Fig. 2 C). After 12 d, all wounds of Fhl2+/− mice were closed, whereas only 80% were closed in Fhl2−/− mice. Importantly, the Fhl2−/−tgSM22Fhl2 transgenic mice that express intermediate Fhl2 mRNA and protein levels in a Fhl2−/− genetic background, displayed a nearly wild-type phenotype, with 30 and 90% wound closure at days 5 and 12, respectively, demonstrating rescue of the wound closure phenotype of Fhl2−/− mice. The same SM22Fhl2 transgene expressed in a Fhl2+/− background, however, did not influence wound healing, indicating that the high levels of Fhl2 expression in Fhl2−/− mice are both necessary and sufficient for efficient wound healing. At each time point, 38–42 lesions were evaluated by measuring wound closure macroscopically, as well as by histological and immunohistochemical staining of skin sections. Collectively, our data indicate that the efficiency of wound closure correlates with the amount of Fhl2 mRNA and protein expression in wounds.

Fibroblasts play a key role in the formation of mechanical forces that lead to wound contraction, which is required to bring the wound margins together. Therefore, we were interested in
correlating the Fhl2 function with extracellular matrix remodeling and contraction. We analyzed the fibroblast-mediated contraction of type I collagen gels as an in vitro model of tissue remodeling. Fibroblasts derived from Fhl2−/− mice displayed a severe defect in collagen contraction, with a half-maximal contraction time of >60 h, compared with 10.4 h in Fhl2+/+ cells (Fig. 3 A). The contraction of a collagen matrix was, in fact, so severely impaired in Fhl2−/− cells that we were unable to measure exactly the half-maximal contraction time within the observation interval. Because bioactive lipids stimulate fibroblast-mediated collagen contraction (Yanase et al., 2000), we analyzed collagen contraction in the presence of S1P. This resulted in a decreased half-maximal contraction time of 8.6 h for Fhl2+/+ fibroblasts (Fig. 3 A). In contrast, S1P did not stimulate collagen contraction mediated by Fhl2−/− fibroblasts. Importantly, ectopic expression of Fhl2 in Fhl2−/− fibroblasts by transfection of an appropriate expression plasmid fully restored the capability to contract collagen (Fig. 3 A), demonstrating that Fhl2 is an essential component in this tissue remodeling assay.

During wound healing, mesenchymal cells differentiate upon stimulation by inflammatory cytokines into myofibroblasts, which produce high amounts of α-SMA and are involved in wound contraction in vivo (Hinz and Gabbiani, 2003). The early phase of wound healing is triggered by serum components released from injured blood vessels and degranulating platelets (Yatomi et al., 2000), which activate the transcription factor SRF (Chai and Tarnawski, 2002). SRF and Fhl2 interact physically (Philippar et al., 2004) and bind to the promoter of the SRF-responsive α-SMA gene. Degranulating platelets release large amounts of bioactive lipids, including S1P and lysophosphatidic acid, into wounds that, in turn, trigger nuclear translocation of Fhl2 (Muller et al., 2002). Therefore, we addressed...
the question of whether Fhl2 may function as a transcriptional cofactor of SRF in activating α-SMA expression during wound healing.

For these assays, we tested cells of different origin (epithelial human embryonic kidney [HEK] 293 cells, mesenchymal stem cells, and fibroblasts), which are devoid of endogenous Fhl2 expression or with a Fhl2 knockout genotype, respectively. These cells were cotransfected with SRF- and Fhl2-expression constructs, together with a reporter plasmid carrying an α-SMA promoter-driven luciferase gene. Although expression of Fhl2 in HEK293 alone did not change reporter activity, we observed between two- and threefold activation in the mesenchymal cells (Fig. 3 B). SRF mediated an approximately fourfold increase of reporter expression in all cell lines. Importantly, expression of both SRF and Fhl2 resulted in approximately two- or threefold higher reporter activity than expression of SRF alone (Fig. 3 B), indicating coactivation of SRF-mediated transcriptional activity in all three cell lines.

We characterized α-SMA expression in myofibroblasts during wound healing in Fhl2−/− and Fhl2+/+ mice. As expected, immunohistochemical staining revealed strong expression of α-SMA in myofibroblasts of the granulation tissue between two- and threefold activation in the mesenchymal cells (Fig. 3 B). SRF mediated an approximately fourfold increase of reporter expression in all cell lines. Importantly, expression of both SRF and Fhl2 resulted in approximately two- or threefold higher reporter activity than expression of SRF alone (Fig. 3 B), indicating coactivation of SRF-mediated transcriptional activity in all three cell lines.

Figure 3. Fhl2 regulates fibroblast contractility and coactivates SRF-mediated α-SMA transcription in wound healing. (A) Defective collagen contraction in Fhl2−/− embryonic fibroblasts (top). Collagen contraction and stimulation in response to treatment with S1P were restored after retransfecting Fhl2 cDNA into Fhl2−/− fibroblasts (bottom). Transfections were done in triplicate, with either empty vector (pcDNA3) or Fhl2 expression plasmid (Fhl2). SDs were <2% in all cases. (B) HEK293, Fhl2−/− fibroblasts (MEFs), and Fhl2−/− mesenchymal stem cells (MSCs) were transfected with an α-SMA promoter-driven luciferase reporter construct and expression plasmids for SRF and Fhl2. Bars indicate the fold induction of transfecting SRF, Fhl2, and both expression vectors versus the luciferase activity of the reporter plasmid. n = 3. Error bars represent the SD. (C) Cutaneous lesions 5 d after applying skin punch wounds to Fhl2−/− and Fhl2+/+ mice. Images show hematoxylin and eosin staining (HE, top) and immunohistochemical stainings for α-SMA expression (bottom). There is strong α-SMA reactivity in the granulation tissue of Fhl2−/−, but not of Fhl2+/+, mice below the reepithelializing keratinocytes on top. Bar, 100 μm.
below the wound surface at day 5 in Fhl2<sup>+/+</sup> mice, but only very weak signals in knockout animals (Fig. 3 C). Systematically scoring the intensity of α-SMA staining in 100 fibroblasts below every wound surface revealed significantly weaker staining in Fhl2<sup>−/−</sup> mice (relative units, 1.25 ± 0.6 at day 5 and 1.4 ± 1.0 at day 12, respectively) than in Fhl2<sup>+/+</sup> mice (relative units, 2.6 ± 0.75 at day 5 and 2.0 ± 0.6 at day 12, respectively). The difference in α-SMA staining intensity was that it was statistically significant at day 5 (P < 0.001) and was still significant at day 12 (P < 0.1). Importantly, immunostainings of the transgenic SM22Fhl2 rescue mouse strain did not reveal any difference in α-SMA reactivity compared with Fhl2<sup>+/+</sup> mice. These results indicate that activation of α-SMA expression in myofibroblasts and wound closure occurred less efficiently and slower in Fhl2<sup>−/−</sup> mice.

Cutaneous wound healing is inevitably associated with migration of mesenchymal precursor cells and their subsequent differentiation into myofibroblasts. Within the first days after wounding, mesenchymal cells invade the wound to replace the clot and to form a granulation tissue. To address the question of whether Fhl2 influences the migration capacity of such cells, we established mesenchymal stem cell lines from bone marrow of Fhl2<sup>+/+</sup> and Fhl2<sup>−/−</sup> mice (Fig. 4 A). The morphology of different Fhl2<sup>−/−</sup> clones was quite similar, but differed from that of Fhl2<sup>+/+</sup> clones. Fhl2<sup>−/−</sup> cells showed a more epithelial-like form and had a less polar shape, often with many short actin stress fibers running in different directions. Fhl2<sup>+/+</sup> cells had a more fibroblast-like form, with many filopodial and lamellipodial structures. They displayed a well-organized actin cytoskeleton with long microfilament cables running across the whole cell body (Fig. 4 A), and Fhl2 was localized at focal adhesion structures, as well as along the actin filaments. Analysis of the migration capacity revealed a motility defect of Fhl2<sup>−/−</sup> cells (Fig. 4 B and Videos 1 and 2, available at http://www.jcb.org/cgi/content/full/jcb.200606043/DC1). Fhl2<sup>−/−</sup> cells showed much less activity in the formation of filopodia or lamellipodia and, consequently, needed almost twice as much time to close a cell-free cleft in comparison with Fhl2<sup>+/+</sup> cells. (Fig. 4 B and Videos 1 and 2). Importantly, ectopic expression of a myc-tagged Fhl2 protein (Fig. S2 A) rescued the impaired migration
activity of the Fhl2⁻/− cells (Fig. 4B and Video 3). The ectopic expression of Fhl2 not only rescued the motility phenotype but also reverted the cell shape and actin cytoskeleton organization to that of Fhl2⁺/⁺ stem cells (Fig. 4A). Impaired cell motility was independent of the substrate on which the cells migrated (fibronectin, laminin-1, or no substrate) and of the cell origin. On uncoated dishes, cell movement was slower, with 10.8 ± 1.4 μm/h for Fhl2⁺/⁺, 5.8 ± 0.9 μm/h for Fhl2⁻/⁻, and 9.6 ± 0.9 μm/h for rescued mesenchymal stem cells. On fibronectin-coated dishes, the migration velocity was 17.1 ± 0.7 μm/h for Fhl2⁺/⁺, 8.8 ± 0.4 μm/h for Fhl2⁻/⁻, and 12.0 ± 1.5 μm/h for Fhl2⁻/⁻-rescued cells, respectively. The diminished migratory activity of Fhl2⁻/⁻ cells was not caused by changes of the integrin pattern on their surface, as Fhl2⁺/⁺, Fhl2⁻/⁻, and rescued cells all expressed equal amounts of integrin β1-containing receptors (Fig. S2B). Like Fhl2⁺/⁺ cells, the Fhl2⁻/⁻ or rescued cells attached equally well to proteins of the extracellular matrix, suggesting that different adhesion properties are not responsible for the reduced migratory capacity.

Interestingly, the impaired cell migration and the cytoskeletal changes of Fhl2⁻/⁻ cells remarkably resemble the phenotype of FAK-deficient cells (Ilic et al., 1995). In addition, it is known that FAK has to be activated for cell migration (Mitra et al., 2005). After adhesion to extracellular matrix molecules, FAK is autophosphorylated at tyrosine Y397, recruiting Src, which in turn phosphorylates FAK at additional Y residues, including Y861, which serves as the binding site for p130Cas. Interaction of p130Cas and FAK leads to recruitment of multiple other proteins, finally resulting in the formation of lamellipodia and cell migration (Playford and Schaller, 2004; Mitra et al., 2005). Analysis of FAK tyrosine phosphorylation showed that the overall phosphorylation pattern was identical in Fhl2⁺/⁺, Fhl2⁻/⁻, and Fhl2⁻/⁻-rescued mesenchymal cell lines (Fig S3, available at http://www.jcb.org/cgi/content/full/jcb.200606043/DC1). Only pY861, serving as the binding site for p130Cas, was slightly hyperphosphorylated in the Fhl2⁻/⁻ cells. We previously showed that Fhl2 directly binds to integrins (Wixler et al., 2000) and FAK (Gabriel et al., 2004), and that it is localized at

![Image](226x54 to 562x480)
focal adhesion sites (Samson et al., 2004). Analysis of immunocomplexes from lysates of Fhl2+/+ and Fhl2−/− cells showed that Fhl2 coimmunoprecipitated with FAK and p130Cas, but not with Src, when cells were plated on fibronectin-coated dishes (Fig. 5 A). Interestingly, the level of p130Cas was significantly reduced in Fhl2−/− cells, whereas the amounts of FAK and Src were not altered (Fig. 5 A). Furthermore, as shown in Fig. 5 B, the level of p130Cas was similar to that of Fhl2+/+ cells when the Fhl2 protein was reexpressed in Fhl2−/− cells.

Next, quantitative real-time PCR experiments were performed to study whether the changes in p130Cas expression levels result from differences in mRNA expression. Amplification curves for p130Cas and, as a reference gene, cyclolinphillin, were obtained with template cDNA from Fhl2+/+ and Fhl2−/− mesenchymal stem cells. Each curve shown in the Fig. S4 A (available at http://www.jcb.org/cgi/content/full/jcb.200606043/DC1) represents the mean of three replicates from a single cDNA sample. The amplification of p130Cas cDNA was delayed in Fhl2−/− cells compared with Fhl2+/+ cells, indicating a lower p130Cas mRNA amount. The difference between the average Ct-value of p130Cas and cyclolinphillin (∆∆Ct) was calculated for both cell lines. These values were compared (∆∆Ct), and the relative amount of p130Cas mRNA was calculated (2-∆∆Ct) and diagrammed (Fig. S4 B). In summary, our data clearly indicate that Fhl2 knockout cells express roughly two-fold lower p130Cas mRNA levels.

Recomputation of p130Cas subsequently leads to activation of Rac and cell migration (Playford and Schaller, 2004; Mitra et al., 2005). Therefore, we asked whether expression of p130Cas in Fhl2−/− mesenchymal stem cells would be able to rescue the defect in cell migration. Knockout stem cells were infected with retroviruses expressing either p130Cas along with GFP or GFP alone as a control. The p130Cas and GFP genes were connected by an internal ribosomal entry-site sequence. Evaluation of GFP-labeled cells indicated that the infection efficiency was 94.1 and 95.2%, respectively (Fig. 5 C, left). Consistently, Western blots indicated robust expression of p130Cas in the knockout cells (Fig. 5 C, right). Analysis of cell motility revealed that the migratory capacity of Fhl2−/− cells that overexpressed p130Cas was enhanced in comparison with Fhl2−/− cells, but did not reach the velocity of Fhl2+/+ cells. These results were obtained independently of whether cells migrated on uncoated or on fibronectin-coated surfaces (Fig. 5 D). Thus, reexpression of p130Cas rescued the migratory phenotype of Fhl2−/− cells, but not entirely to the level of Fhl2+/+ cells.

Finally, we asked whether changes in expression of p130Cas resulted in different levels of Rac activation. Therefore, Fhl2+/+, knockout, and Fhl2−/− cells stably expressing p130Cas or the empty vector were assayed for Rac activity. The cells were serum-starved overnight, trypsinized, and plated for 15, 30, or 60 min, respectively, on cell culture dishes precoated with 20 mg/ml fibronectin. For precipitation of GTP-loaded Rac, cells were lysed in Triton X-100 lysis buffer, and 400 mg protein were rotated with GST-PAK3–coated glutathione beads. Although the activation kinetics slightly varied in separate experiments, a reproducible difference in the Rac activation between Fhl2+/+ and Fhl2−/− cells was observed. Data shown in Fig. 5 E clearly indicate that knockout cells activate Rac less efficiently than Fhl2+/+ cells, and that Fhl2−/− cells reconstituted with p130Cas restore their capability to activate Rac in response to attachment to fibronectin.

**Discussion**

Previous studies, mainly based on cell lines in vitro, established Fhl2 as a serum-responsive signal transducer shuttling in response to SP1 and lysosphatidic acid from the cell membrane into the nucleus, where it functions as a nuclear coactivator of transcription factors. However, only few transcriptional targets, including Fhl2 itself, were described, and the function of Fhl2 signaling in vivo is much less explored. Although a function of Fhl2 in promoting differentiation of myoblasts was suggested (Martin et al., 2002), Fhl2 knockout mice developed only a mild phenotype with bone formation defects and an increased sensitivity in respect to a hypertrophic response to β-adrenergic stimulation in the heart (Kong et al., 2001; Bai et al., 2005; Gunther et al., 2005; Lai et al., 2006).

Data presented in our study indicate that Fhl2 further mediates nonredundant signaling during wound healing. Fhl2−/− mice clearly revealed delayed wound healing, reduced migration of mesenchymal precursor cells, delayed activation of α-SMA, and impaired wound contraction. The Fhl2 protein is activated in dermal fibroblasts after release of bioactive lipids in woundtissue and, indeed, we show that Fhl2 regulates the expression of α-SMA by coactivation of SRF, and thereby the contractility of the granulation tissue. Therefore, it seems that nuclear shuttling and transcriptional coactivation of Fhl2 developed as a signaling pathway mediating rapid adaptation of cells and tissues in response to pathological stress conditions. Our data further indicate that Fhl2 signaling is cell-type specific and different from its function in cardiac muscle cells, where it negatively regulates expression of SMA (Philipp et al., 2004).

In addition, Fhl2 interacts with proteins of focal adhesion structures at the membrane or cytosolic level, and we provide first evidence that because of this interaction Fhl2 regulates cell motility and contractility. Contraction of the granulation tissue facilitates wound closure by bringing the wound margins together. Efficient contraction of myofibroblasts requires a well-developed cytoskeleton, which is established by expression of α-SMA and its incorporation into actin stress fibers (Hinz and Gabbiani, 2003). Hence, expression of α-SMA by skin fibroblasts is a critical step in wound healing. Interestingly, our data for the first time provide a mechanistic link between release of the bioactive lipids S1P and lysosphatidic acid from platelets during clotting and wound healing and the contractile activity of the granulation tissue. These substances trigger, in a Rho-dependent manner, nuclear shuttling of Fhl2 (Muller et al., 2002) where it acts as a coactivator of α-SMA transcription. Consistent with these data, we further demonstrated that in the absence of Fhl2, the contractile forces of fibroblasts are dramatically reduced and that this defect can be rescued by expression of exogenous Fhl2 protein.

It is well known that FAK plays a key role in cell migration. It is activated upon integrin engagement and recruits several
cytosolic proteins that drive cell migration. We show that the expression of the downstream signaling molecule p130Cas, which regulates the activity of the Rac GTPase, and hence, cell migration, is down-regulated in Fhl2−/− cells. Our data, however, also indicate that the mechanism by which Fhl2 regulates cell migration is more complex and cannot be reduced just to the level of p130Cas protein, as its overexpression did not restore migration velocity of mesenchymal cells to the full level of Fhl2+/+ cells. Thus, it appears that Fhl2 activation in mesenchymal cells after wounding regulates different effector functions of activated FAK. A separate study of our group provided evidence that Fhl2 is also involved in organization of focal adhesion structures and in regulation of matrix assembly (unpublished data).

In summary, we show for the first time that Fhl2−/− mice display a cutaneous wound-healing phenotype that can be rescued by ectopic expression of Fhl2. Our data demonstrate reduced expression of α-SMA and p130Cas and, subsequently, less efficient activation of Rac in Fhl2−/− cells, which lead to severe defects in collagen contraction and migration. Thus, lipid-triggered Fhl2 signaling is mechanistically involved in regulating wound healing and may represent a new therapeutic target.

Materials and methods

Fhl2−/− and transgenic mice

Fhl2−/− mice were provided by R. Bassel-Duby (University of Texas Southwestern Medical Center, Dallas, TX) and published previously [Kong et al., 2001]. For the generation of transgenic mice, the human Fhl2 cDNA was coupled with a 1.4kb SM22a promoter [Jain et al., 1998] and animals were obtained according to published procedures [Jager et al., 2003]. Genotyping was done by PCR analysis from tail genomic DNA using the primer pairs 5′-GAGCTCCTCAACTGCTTCTTCC-3′ and 5′-TCCCGCAGAGGTGACTCTGTC-3′ in 35 amplification cycles (95°C for 30 s, 54°C for 30 s, and 72°C for 30 s). All animals were maintained in a pure C57BL/6 background, and subpairs were used for the wound-healing experiments.

Wound-healing experiments

48 6-wk-old mice (18 Fhl2−/−, 18 Fhl2+/−, and 12 transgenic mice) were used. 2–4 0.6-cm punch wounds, including the skin and cutaneous muscle, were cut into each mouse and left to heal by secondary intention, essentially as previously described (Ashcroft et al., 1999). At days 0, 5, and 12, wounds were dissected and paraffin-embedded for histology or homogenized in 150 mM NaCl, 10 mM Tris, pH 7.2, 0.1% SDS, 1% Triton X-100, and 1% deoxycholate and centrifuged at 13,000 g for 20 min at 4°C. 15 μg of protein lysates were denatured at 90°C for 10 min, run on 12% SDS/PAGE gels, and electroblotted to a PVDF membrane (Roth-PVDF, Roth GmbH) using standard protocols. After blocking in 5% nonfat dry milk/PBS for 2 h, the membranes were incubated for 1 h with a monoclonal anti-Fhl2 antibody (dilution 1:2,000), washed, incubated with horseradish peroxidase–conjugated secondary antibody (dilution 1:1,000; DacoCytomation), and developed using ECL chemiluminescence (GE Healthcare). As a control, blots were probed with a primary anti-β-Actin antibody (dilution 1:5,000; DacoCytomation). Images were captured on film, digitized, and if needed, minor linear adjustments in contrast were made using Photoshop software (Adobe).

Quantitative real-time PCR

Total RNA was extracted with the RNeasy kit (QIAGEN) from two independent samples of Fhl2−/− and Fhl2+/− stem cells, respectively. Reverse transcription of RNA (1.5 μg) was performed with oligo(dT) primers and ReverTra Aid H-Minus M-MuLV reverse transcriptase (Fermentas MB). For PCR amplification of cDNA, specific primers (MWG) were used to detect differences in the expression levels of p130Cas; primers for murine p130Cas were chosen according to Jayanti et al. (2002). Primers for the reference gene cyclophilin were as follows: 5′-CCACCGTGTCCTTCGACAT-3′ (upstream) and 5′-CATGCTCACAGCTTCGAAAG-3′ (downstream). The PCR reactions were done in triplicate for each cDNA after the Stratagene protocol with 2× Brilliant SYBR Green QPCR Master Mix (Stratagene), with preheating at 95°C for 10 min; 40 cycles of 95°C for 10 s, 60°C for 1 min, and 72°C for 30 s; and 95°C for 1 min, 60°C for 30 s, and 95°C for 30 s. MxPro Software (Stratagene) was used for analysis.

Immunostaining and acquisition of images

4–μm tissue slices were cut from formalin-fixed and paraffin-embedded wound specimens and used for staining with hematoxylin and eosin or by immunohistochemistry. Indirect immunohistochemistry was done by the avidine–biotin method, as previously described (Friedrichs et al., 2005). Primary antibodies were anti-human α-SMA (1:25 dilution; DacoCytomation), anti-SM22 (1:100 dilution; DacoCytomation), anti–cytokeratin-5 (1:100 dilution; DacoCytomation), and anti–collagen type I (1:110 dilution; ICN Biochemicals). Slides were incubated with a secondary goat anti–mouse serum (dilution 1:200; DacoCytomation), reacted with the ABC kit (Vector Laboratories), and peroxidase activity was visualized with 3-aminon-9-ethylcarbazole (Sigma-Aldrich). Double immunostaining with a second alkaline phosphatase–labeled antibody (DacoCytomation) was done as previously described (Friedrichs et al., 2005). Pictures were taken by using a light microscope DM LB2 (leica) and the analysis system software Diskus (Hilgler).

For immunofluorescence staining, 5 × 105 fibroblasts were seeded in chamber slides (Nunc), grown to 75% confluency, and incubated for 48 h in medium containing 10% or 0.5% FCS. Indirect immunofluorescence staining was done as previously described (Muller et al., 2002), using rabbit anti-Fhl2 antibody (1:300), anti-Fhl2 mAb clone F482 (Samson et al., 2004), or anti-myc mAb derived from clone 9E10 (American Type Culture Collection). Cell images were taken using an Axiosvert 2000 ApoTome microscope with an AxioCam digital camera and AxioVision software (Carl Zeiss MicroImaging, Inc.).

Cell transfections and luciferase assays

Transfections of 293 cells and luciferase assays were performed as previously described (Muller et al., 2002). 500 ng of the reporter plasmid pSM8pGL3 were cotransfected with expression plasmids coding for SRF
(2.5 ng) and Fhl2 (5 ng pCMX-Fhl2) as indicated. Transfections of Fhl2−/− fibroblasts were performed with Lipofectamine (Invitrogen), and transfections of Fhl2+/− cells were performed with Fugene 6 (Roche) as recommended by the manufacturer. Relative light units were normalized to protein concentration using the Bradford dye assay (BioRad Laboratories). For construction of pSM6G3α, the α-SMA promoter and the first intron (SPMA); a gift from E.P. Smith, University of Cincinnati College of Medicine, Cincinnati, OH) were cloned in pG3 (Promega). SPMA contains −1,074 bp of the 5′-flanking region, 63 bp of 5′-UT, and the 2.5 kb first intron of the α-SMA.

For generation of p130Cas retrovirus stocks, the CDNA of human p130Cas [a gift from K.H. Kirsch, Boston University Medical School, Boston, MA] was cloned into the bicistronic retroviral pEGZ vector before the internal ribosomal entry-site sequence and the GFP gene. After transfection of Phoenix virus producer cells (Orbigene, Inc.) with pEGZ vector alone or pEGZ-p130Cas, the cells were selected for zeocin resistance, and supernatants from confluent monolayers were used as retroviral stocks.

Cell migration assay
Cell migration studies were performed essentially as previously described (Lavrovskii and Razvorotnev, 1976). In brief, 5 × 105 cells in 0.8 ml of DMEM with 10 ng/ml EGF and PDGF were plated onto 48-well plates, which were precoated with fibronectin, laminin-1, or nothing and blocked with 1% BSA. To produce a cell-free “window,” 1-mm-thick steel plates were inserted into wells before seeding the cells and were removed again after the cells had been attached to the bottom. This method has the advantage over the frequently used “scratch window” assay that in the substrate in the window is not destroyed. The migration was monitored by inverted microscopy at the times indicated. For videos, the scratch assay was used.

Flow cytometry
105 cells were suspended in FACSBACS (PBS containing 2% FCS and 0.02% NaN3). Cells were incubated with integrin anti–the animal experiments, and G. Gabbiani for helpful discussions.

References
Ashcroft, G.S., X. Yang, A.B. Glick, M. Weinstein, J.L. Letterio, D.E. Miził, M. Amling, and R. Schuler. 1999. Mice lacking Smad3 show accelerated wound healing and mechanical loading. Trends Cell Biol. 10:362–365.

Bell, E., B. Ivarsson, and C. Merrill. 1979. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc. Natl. Acad. Sci. USA. 76:1274–1278.

Bhuiya, A., T. Datta, and J. Frank. 1995. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. J. Cell. Biol. 136:1539–544.

Bhatt, S.K., D.A. Hanson, and D.D. Schlaepfer. 2005. Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer. Anticancer Res. 24:921–927.

Grinnell, F. 2000. Fibroblast-collagen-matrix contraction: growth-factor signaling and mechanical loading. Trends Cell Biol. 10:362–365.

Gunther, T., C. Poli, J.M. Muller, P. Catala-Lehnen, T. Schinke, N. Yin, S. Voesten, M. Ameling, and R. Schuler. 2005. Fhl2 deficiency results in osteopenia due to decreased activity of osteoblasts. EMBO J. 24:3049–3056.

Hamm, A., N. Krott, I. Breibach, R. Blintt, and A.K. Bosserhoff. 2002. Efficient transfection method for primary cells. Tissue Eng. 8:235–245.

Hinz, B., and G. Gabbiani. 2003. Cell-matrix and cell-cell contacts of myofibroblasts: role in connective tissue remodeling. Thromb. Haemost. 90:993–1002.

Ilic, D., Y. Furuta, S. Kanazawa, T. Takeda, K. Sobue, N. Nakatsuji, S. Nomura, J. Fujimoto, M. Okada, and T. Yamamoto. 1995. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature. 375:539–544.

Jagers, R., U. Wierling, S. Rimpf, A. Jacob, and H. Scholer. 2003. Transcription factor AP-2gamma stimulates proliferation and apoptosis and impairs differentiation in a transgenic model. Mol. Cancer Res. 1:921–929.

Jiang, J., K. Jokinen, K. Lai, L. Lin, J. Shi, and M. Wang. 2005. Cardiac-specific LIM protein FHL2 modulates the hypertrophic response to beta-adrenergic stimulation. Circulation. 103:2731–2738.

Lai, C.F., S. Bai, B.A. Uthgenannt, L.R. Halstead, P. McLoughlin, B.W. Schafer, P.H. Chu, J. Chen, C.A. Otey, X. Cao, and S.L. Cheng. 2006. Four and half lim protein 2 (FHL2) stimulates osteoblast differentiation. Bone Miner. Res. 21:17–28.

Lavrovskii, V.A., and V.A. Razvorotnev. 1976. (A chamber for determination of the rate of macrophage migration under different experimental conditions). Tsitologiia. 18:113–116.

Martin, B., R. Schneider, S. Janetzky, Z. Waibler, P. Pandur, M. Kuhl, J. Behrens, K. von der Mark, A. Starzinski-Powitz, and V. Wixler. 2002. The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts. J. Cell Biol. 159:113–122.

Mitra, S.K., D.A. Hanson, and D.D. Schlaepfer. 2005. Focal adhesion kinase: in command and control of cell motility. Nat. Rev. Mol. Cell Biol. 6:56–68.

Morlon, A., and P. Sassone-Corsi. 2003. The LIM-only protein FHL2 is a serine-inducible transcriptional coactivator of F-actin. Proc. Natl. Acad. Sci. USA. 100:3977–3982.

Muller, J.M., U. Isele, E. Metzger, A. Rempel, M. Moser, A. Pachere, T. Breuer, C. Holubarsch, R. Buettner, and R. Schuler. 2000. FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J. 19:359–369.

Muller, J.M., E. Metzger, H. Greschik, A.K. Bosserhoff, L. Mercpep, R. Buettner, S. Schuler, and R. Schuler, 2002. The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts. J. Cell Biol. 159:113–122.

Mitra, S.K., D.A. Hanson, and D.D. Schlaepfer. 2005. Focal adhesion kinase: in command and control of cell motility. Nat. Rev. Mol. Cell Biol. 6:56–68.

Morlon, A., and P. Sassone-Corsi. 2003. The LIM-only protein FHL2 is a serum-inducible transcriptional coactivator of F-actin. Proc. Natl. Acad. Sci. USA. 100:3977–3982.

Muller, J.M., U. Isele, E. Metzger, A. Rempel, M. Moser, A. Pachere, T. Breuer, C. Holubarsch, R. Buettner, and R. Schuler. 2000. FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J. 19:359–369.

Muller, J.M., E. Metzger, H. Greschik, A.K. Bosserhoff, L. Mercpep, R. Buettner, S. Schuler, and R. Schuler, 2002. The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts. J. Cell Biol. 159:113–122.

Park, J., K. Gelse, S. Frank, K. von der Mark, T. Aigner, and H. Schneider. 2006. Transgene-activated mesenchymal cells for articular cartilage repair: a comparison of primary bone marrow-, perichondrium/perosteum- and fat-derived cells. J. Gene Med. 8:112–125.

Philippip, U., G. Schratt, C. Dietrich, J.M. Muller, P. Galgcocz, F.B. Engel, M.T. Keating, F. Gertler, P. Schule, M. Vlunrong, and A. Nordheim, 2004. The SRF target gene Fhl2 antagonizes RhoA/MAL-dependent activation of SRF. Mol. Cell. 16:867–880.

Playford, M.P., and M.D. Schaller. 2004. The interplay between Src and integrins in normal and tumor biology. Oncogene. 23:7928–7946.

Purcell, N.H., D. Darwis, O.F. Bueno, J.M. Muller, R. Schuler, and J.D. Molkenpick. 2004. Extracellular signal-regulated kinase 2 interacts with
and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol. Cell. Biol. 24:1081–1095.

Samson, T., N. Smyth, S. Janetzky, O. Wendler, J.M. Muller, R. Schule, H. von der Mark, K. von der Mark, and V. Wixler. 2004. The LIM-only proteins FHL2 and FHL3 interact with alpha- and beta-subunits of the muscle alpha?beta1 integrin receptor. J. Biol. Chem. 279:28641–28652.

Wixler, V., D. Geerts, E. Laplantine, D. Westhoff, N. Smyth, M. Aumailley, A. Sonnenberg, and M. Paulsson. 2000. The LIM-only protein DRAL/FHL2 binds to the cytoplasmic domain of several alpha and beta integrin chains and is recruited to adhesion complexes. J. Biol. Chem. 275:33669–33678.

Yanase, M., H. Ikeda, A. Matsu, H. Maekawa, E. Noiri, T. Tomiya, M. Arai, T. Yano, M. Shibata, M. Ikebe, et al. 2000. Lysophosphatidic acid enhances collagen gel contraction by hepatic stellate cells: association with rho-kinase. Biochem. Biophys. Res. Commun. 277:72–78.

Yatomi, Y., T. Ohmori, G. Rile, F. Kazama, H. Okamoto, T. Sano, K. Satoh, S. Kume, G. Igarashi, and Y. Ozaki. 2000. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood. 96:3431–3438.